DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections

Intervention: Zidovudine (Drug); Zalcitabine (Drug)

Phase: N/A

Status: Completed

Sponsored by: Hoffmann-La Roche

Summary

To provide zalcitabine ( dideoxycytidine; ddC ) for use with zidovudine ( AZT ) in patients with advanced HIV infection. To observe serious toxicities in this population.

Clinical Details

Official title: Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease

Study design: Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment

Detailed description: Patients are treated with 1 of 2 doses of ddC administered orally (PO) in combination with AZT administered PO (patients who are unable to tolerate this dose of AZT may receive a lower dose).

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Concurrent Medication: Allowed:

- Concomitant use of investigational compounds for prophylaxis or treatment of

opportunistic infections or other treatments provided use of those compounds with ddC-AZT is considered safe. Patients must have:

- Documented HIV infection OR documented AIDS-defining opportunistic infection or

neoplasm.

- Previous AIDS-defining opportunistic infection, neoplasm, or condition OR CD4

lymphocyte count equal to or less than 300 cells/mm3 if symptomatic ORCD4 lymphocyte count equal to or less than 200 cells/mm3 if asymptomatic.

- Patients must not be currently enrolled in or must be unable to enter an AIDS

Clinical Trials Group (ACTG), Community Programs for Clinical Research on AIDS (CPCRA), or other controlled clinical program because of patient ineligibility, distance from trial site, or patient refusal.

- Patients currently enrolled in any controlled clinical trial of an anti-HIV compound

may enter this program only if they have met the end points required for termination of that trial.

- Patients may be co-enrolled in clinical programs of investigational compounds being

tested for prophylaxis or treatment of opportunistic infections or other treatments provided that program allows ddC-AZT combination use, and concomitant administration of the other investigational drug and ddC-AZT is considered safe by the investigator. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded:

- Any clinical or laboratory toxicity or abnormality, particularly the presence or

history of moderate to severe peripheral neuropathy, that would pose an undue risk to the patient upon initiation of ddC-AZT treatment.

- Pregnancy.

Locations and Contacts

ddC Coordinating Ctr, Wellesley Hills, Massachusetts 021810003, United States
Additional Information

Related publications:

Walker M, Moyle GJ, Harris R, Warburg M. Safety and efficacy of zalcitabine (ddC) and zidovudine (ZDV) combination in HIV-positive persons with CD4 cell counts less than or equal to 300/mm3: an international open label evaluation (Roche study M50002). Int Conf AIDS. 1996 Jul 7-12;11(1):77 (abstract no MoB1129)


Last updated: June 23, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017